Optinose Reports Third Quarter 2017 Financial Results and Recent Operating Highlights
OptiNose, Inc. (OPTN)
Last optinose, inc. earnings: 3/5 06:30 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.optinose.com
Company Research
Source: GlobeNewswire
YARDLEY, Pa., Nov. 27, 2017 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today reported financial results for the quarter ended September 30, 2017, and provided recent operational highlights. “Following our successful initial public offering in October, we are well-positioned to launch XHANCE in the second quarter of 2018,” said Optinose chief executive officer Peter Miller. “With an outstanding leadership team in place, we expect an exciting and productive year ahead as we work to deliver XHANCE to patients in need. We believe XHANCE has the potential to improve the lives of millions of patients who are searching for new treatment options and lays a strong foundation for Optinose to become a leading ENT/allergy company.” Third Quarter 2017 and Recent Highlights FDA Approval of XHANCE: The U.S. Food & Drug Administration approved the Company’s New Drug Application for XHANCE
Show less
Read more
Impact Snapshot
Event Time:
OPTN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
OPTN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
OPTN alerts
High impacting OptiNose, Inc. news events
Weekly update
A roundup of the hottest topics
OPTN
News
- Optinose Provides Corporate Update on XHANCE Launch and Outlook and Announces Preliminary First Quarter 2024 XHANCE Net Revenue of $14.9 million [Yahoo! Finance]Yahoo! Finance
- Optinose Provides Corporate Update on XHANCE Launch and Outlook and Announces Preliminary First Quarter 2024 XHANCE Net Revenue of $14.9 millionGlobeNewswire
- OptiNose (NASDAQ:OPTN) shareholders have endured a 87% loss from investing in the stock five years ago [Yahoo! Finance]Yahoo! Finance
- Optinose to Present at the Needham Virtual Healthcare ConferenceGlobeNewswire
- OptiNose, Inc. (NASDAQ: OPTN) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $5.00 price target on the stock.MarketBeat
OPTN
Earnings
- 3/7/24 - Beat
OPTN
Sec Filings
- 4/26/24 - Form DEFA14A
- 4/26/24 - Form DEF
- 4/25/24 - Form SC
- OPTN's page on the SEC website